Biogen Stock News

It's possible.

Biogen, other drug companies are furiously contesting Medicare''s preliminary decision to pay for a class of Alzheimer''s drugs only in clinical trials.

Sage Therapeutics (SAGE) and Biogen's (BIIB) depression candidate, zuranolone given along with antidepressants improves depressive symptoms in a phase III study. Questions remain about the durability

NEW YORK, Feb. 17, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Biogen investors who were adversely affected…

Biogen Inc (BIIB) shares closed today at 1.5% above its 52 week low of $211.29, giving the company a market cap of $31B. The stock is currently down 9.4% year-to-date, down 21.8% over the past 12 months, and down 25.7% over the past five years. This week, the Dow Jones Industrial Average fell 1.2%, and the S&P 500 fell 1.1%. Trading Activity Trading volume this week was 45.7% lower than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.5. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 30.4% The company's stock price performance over the past 12 months lags the peer average by 1083.5% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -47.4% lower than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Sage Therapeutics Inc (NASDAQ: SAGE ) and Biogen Inc (NASDAQ: BIIB ) said zuranolone combined with a standard of care antidepressant met the primary goal of showing rapid and significant reduction in depressive symptoms in a late-stage study . The drug, zuranolone, also met the study''s secondary goal of showing an improvement in symptoms … Full story available on Benzinga.com

NEW YORK, Feb. 16, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice on behalf of shareholders of Biogen Inc.. Shareholders who purchased shares of BIIB during the class period… | February 16, 2022

NEW YORK, Feb. 16, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice on behalf of shareholders of Biogen Inc.. Shareholders who purchased shares of BIIB during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment….

By a narrow vote of 50-46, the Senate has confirmed Robert Califf to run the FDA. Califf, who previously served as the FDA commissioner from February 2016 to January 2017, takes over interim chief

The company and Biogen said the data showed the drug speeds up the reduction of symptoms when begun with a standard-of-care antidepressant.

Shares of Sage Therapeutics Inc. tumbled 11.2% in premarket trading on Wednesday after Wall Street raised questions about the durability of the experimental treatment for major depressive disorder that Sage is developing with Biogen Inc. . Biogen''s stock was up 0.7% in premarket trading. The companies had announced Monday morning that zuranolone met the primary endpoint in a Phase 3 clinical trial; however, some analysts still have concerns about the commercial appeal of the drug, if it is approved by the Food and Drug Administration. The data demonstrated that there was no statistical difference between giving zuranolone with an antidepressant and an antidepressant with placebo at the 42-day mark. "Some suggestion of near-term durability would be key to broaden commercial uptake of the agent (and perhaps ensure FDA comfort with the consistency of effects across the studies)," RBC Capital Markets analyst Brian Abrahams told investors on Monday. Sage''s stock is down 48.4% over the past year, while the broader S&P 500 is up 15.2%.

All of them are directly related to Aduhelm.

All of them are directly related to Aduhelm.

Sage (SAGE) and Biogen (BIIB) announced that their Phase 3 CORAL study for zuranolone met primary and key secondary endpoints in adults with major depressive disorder ((MDD))

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hookipa Gets $15M Upfront Payment And Equity Investment From Gilead Following Amended HIV Study Agreem